GERON CORP Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- GERON CORP stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $314.00K, a 37.20% decline year-over-year.
- GERON CORP stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $500.00K, a 36.61% increase year-over-year.
- GERON CORP stock issued during period, value, employee stock purchase plan for the quarter ending 2024-06-30 was $366.00K.
- GERON CORP stock issued during period, value, employee stock purchase plan for fiscal 2025 was $747.00K.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $314.00K 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $747.00K 10-K · filed 2026-03-02 | |
| 2025-06-30 | $500.00K 10-Q · filed 2026-08-05 | |
| 2024-06-30 | $366.00K 10-Q · filed 2025-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |